1. Amlot P, Bacon P, Belch JJF, Black CM, Bois RM du, Briggs D, Denton CP, UK Sceleroderma Study Group (1998) How can treatment of systemic sclerosis be improved ? BMJ 1998; 317: 294
2. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RI, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132: 425
3. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296
4. Black CM, Halkier-Sorensen L, Belch II, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR (1998) Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 37: 952
5. Black CM, Silman AJ, Herrick Al, Denton CP, Wilson H, Newman J,Pompon L, Shi-Wen X (1999) Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 42: 299